Abstract
The combination of mitomycin C and vinblastine in the dose and schedule used in this study (6 and 5 mg/m2, respectively, every 14 days) was of little clinical efficacy in the management of metastatic breast cancer already refractory to standard chemotherapy and hormonal therapeutic approaches.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2113-2115 |
| Number of pages | 3 |
| Journal | Cancer Treatment Reports |
| Volume | 62 |
| Issue number | 12 |
| State | Published - Dec 1 1978 |
ASJC Scopus subject areas
- Oncology
- Cancer Research
Fingerprint Dive into the research topics of 'Phase II study of mitomycin C and vinblastine in women with advanced breast cancer refractory to standard cytotoxic therapy'. Together they form a unique fingerprint.
Cite this
Denefrio, J. M., East, D. W., Troner, M. B., & Vogel, C. L. (1978). Phase II study of mitomycin C and vinblastine in women with advanced breast cancer refractory to standard cytotoxic therapy. Cancer Treatment Reports, 62(12), 2113-2115.